摘要
目的观察肿瘤标志物癌抗原125(CA125)在心力衰竭治疗过程中的变化及与心功能之间的关系。方法对142例慢性心力衰竭(CHF)患者按纽约心功能分级分组,用化学发光免疫法测定患者入院后及出院前血清CA125水平,并通过超声心动图测定左室舒张末期内径(LVEDD)、左室收缩末内径(LVESD)及射血分数(EF)。结果 NYHAⅢ～Ⅳ级组的CA125水平明显高于NYHAⅡ级组(P<0.05);NYHAⅢ～Ⅳ级组的LVEDD显著高于NYHAⅡ级组(P<0.05),NYHAⅢ～Ⅳ级组的LVESD显著高于NYHAⅡ级组(P<0.05),NYHAⅢ～Ⅳ级组的EF显著低于NYHAⅡ级组(P<0.05);CA125水平NYHAⅡ级治疗前为(19.5±8.4)U/mL,治疗后为(9.7±4.5)U/mL;NYHAⅢ～Ⅳ级治疗前为(116.3±65.7)U/mL,治疗后为(37.1±24.6)U/mL。结论 CHF患者血清CA125水平与心功能恶化的程度呈高度正相关,并且可以作为观察CHF治疗效果和判断预后的一个指标。
Objective To observe the tumor marker CA125 changes in the course of treatment of heart.failure and cardiac function. Methods 142 cases of CHF patients were grouped with New York Heart Association classifica- tion,chemiluminescence immunoassay was used for detecting serum CA125 levels of patients after admission and be- fore discharge, and left ventricular end-diastolic diameter （LVEDD）, left ventricular systolic the end diameter （LVESD） ,ejection fraction （EF） were detected by echocardiography. Results CA125 level of group NYHAⅢ - Ⅳ was significantly higher than group NYHA Ⅱ （P〈0. 05）. LVEDD of group NYHAⅢ- Ⅳ was significantly higher than group NYHA Ⅱ. LVESD of group NYHA Ⅲ- Ⅳ was significantly higher than group NYHA Ⅱ. EF of group NYHAⅢ- Ⅳ was significantly lower than group NYHA Ⅱ. Before treatment, The CA125 level of group NYHA Ⅱ was （19.5±8.4）U/mL,after treatment,it was （9.7±4.5） U/mL. Before treatment,The CA125 level of group NY- HAⅢ- Ⅳ was （116.3±65.7） U/mL,But after treatment,it was（ 37.1±24.6）U/mL. Conclusion In CHF pa- tients,serum CA125 level is positively correlated with the degree of deterioration of heart function,it can be used as an indicator to observe the treatment and prognosis of CHF.
出处
《检验医学与临床》
CAS
2012年第15期1858-1859,1861,共3页
Laboratory Medicine and Clinic
